Clinical trials: Breast Cancer, Metastatic
Brain Metastasis
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
The incidence of brain metastasis of Her2-negative breast cancer is high, which seriously affects the prognosis of patients.The treatment of brain metastasis of Her2-negative breast cancer is still tricky.
- Trial name
- NCT06462079
- Testing
- Sacituzumab Govitecan, Radiotherapy
- Volunteers
- 43 people
- Sponsor
- Guangzhou Medical University
HER2-low Breast Cancer
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
- Trial name
- NCT06957886
- Testing
- BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
- Where
- 2 sites in China
- Volunteers
- 566 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer, Metastatic Bone Disease
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
This is a 4-week study to examine the effects of a new experimental medication on women with breast cancer and established bone metastases. This study will enroll approximately 45 women.
- Trial name
- NCT00399802
- Testing
- ZA, Odanacatib
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm of Breast
Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer
To compare the efficacy of the addition of a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone, on the management of adverse events (AEs) related to adjuvant hormone…
- Trial name
- ETAPH (NCT04794075)
- Testing
- Therapeutic Education and Nursing Support Program for Supportive Care
- Where
- 9 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Emile Roux
Breast Cancer
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Triple negative breast cancer (TNBC) has attracted much attention due to its young age of onset, high aggressiveness, lack of clear therapeutic targets and poor clinical prognosis.Eribulin is a novel non-taxane anti-microtubule…
- Trial name
- NCT07255612
- Testing
- Trilaciclib, Eribulin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer
- Trial name
- NCT05574881
- Testing
- Dalpiciclib, Fulvestrant, Pertuzumab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer, Endometrial Cancer
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the…
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Trial name
- NCT03394027
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and…
- Trial name
- OCDMBC (NCT07704801)
- Testing
- CDK4/6 inhibitors
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Sohag University
Breast Cancer, Metastasis
Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer
This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify germ line genetic factors that influence the risk of metastatic breast cancer. 1500 patients will be enrolled in this study.
- Trial name
- StoRM (NCT01460186)
- Testing
- Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)
- Where
- 17 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Metastatic Breast Cancer
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast…
- Trial name
- NCT00404066
- Testing
- Lapatinib, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- George Albert Fisher
Breast Cancer
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds.
- Trial name
- NCT00191451
- Testing
- Gemcitabine, Carboplatin, Herceptin
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01720602
- Testing
- vorinostat, anastrozole, letrozole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Breast Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2…
- Trial name
- VIKTORIA-1 (NCT05501886)
- Testing
- Gedatolisib, Palbociclib, Fulvestrant
- Where
- 235 sites in United States, Argentina and 21 more
- Volunteers
- 701 people
- Sponsor
- Celcuity Inc
Breast Cancer
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the…
- Trial name
- NCT03483012
- Testing
- Atezolizumab, Stereotactic radiosurgery (SRS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor…
- Trial name
- NCT05950945
- Testing
- Trastuzumab Deruxtecan
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Breast Cancer
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00014430
- Testing
- trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, HR+/HER2-negative Breast Cancer
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
The clinical efficacy of fulvestrant and/or palbociclib in the population of patients with metastatic lesions harboring ESR1 mutations was reported.
- Conditions
- Breast Cancer, HR+/HER2-negative Breast Cancer, Metastasis
- Trial name
- PALPETBIO (NCT03560856)
- Testing
- Fulvestrant + palbociclib
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphatic Metastasis, Breast Neoplasms
Ultrasound-Guided Core Needle Biopsy to Assess Sensitivity and Specificity of Axillary Lymph Node Metastasis in Breast Cancer
This study plans to find the most suitable lymph node cortex thickness and abnormal lymph node features to define suspicious lymph nodes.
- Trial name
- NCT07573657
- Volunteers
- 200 people
- Sponsor
- The First Hospital of Jilin University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.